STATE OF WISCONSIN INVESTMENT BOARD - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.

Quarter-by-quarter ownership
STATE OF WISCONSIN INVESTMENT BOARD ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q3 2023$2,910,633
+3.5%
32,492
-1.6%
0.01%
+12.5%
Q2 2023$2,812,515
-4.0%
33,034
-6.7%
0.01%
-11.1%
Q1 2023$2,931,005
-5.2%
35,420
-9.9%
0.01%
-10.0%
Q4 2022$3,090,630
-1.7%
39,296
-7.4%
0.01%0.0%
Q3 2022$3,143,000
+5.6%
42,457
-7.0%
0.01%
+25.0%
Q2 2022$2,977,000
-29.0%
45,673
-31.1%
0.01%
-11.1%
Q1 2022$4,191,000
+19.2%
66,3000.0%0.01%
+28.6%
Q4 2021$3,517,000
-24.9%
66,3000.0%0.01%
-30.0%
Q3 2021$4,680,000
+560.1%
66,300
+938.7%
0.01%
+400.0%
Q1 2021$709,000
-6.8%
6,383
-0.4%
0.00%0.0%
Q4 2020$761,000
+30.8%
6,410
-3.9%
0.00%
+100.0%
Q3 2020$582,000
-92.1%
6,670
-91.9%
0.00%
-95.0%
Q2 2020$7,393,000
-2.4%
82,550
+8.6%
0.02%
-20.0%
Q1 2020$7,574,000
-13.3%
76,0000.0%0.02%
+13.6%
Q4 2019$8,732,000
-8.9%
76,0000.0%0.02%
-15.4%
Q3 2019$9,587,000
+1.6%
76,000
-71.9%
0.03%
-23.5%
Q3 2014$9,436,000
-1.0%
270,2060.0%0.03%0.0%
Q2 2014$9,533,000
-1.3%
270,206
-8.8%
0.03%
-8.1%
Q1 2014$9,660,000
-22.6%
296,4240.0%0.04%
-22.9%
Q4 2013$12,488,000
-1.3%
296,424
-6.6%
0.05%
-7.7%
Q3 2013$12,654,000
-34.4%
317,298
-32.0%
0.05%
-35.8%
Q2 2013$19,282,000466,3230.08%
Other shareholders
HAEMONETICS CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Millrace Asset Group, Inc. 19,264$1,7262.13%
Parkman Healthcare Partners LLC 88,962$7,969,2161.46%
HEARTLAND ADVISORS INC 256,414$24,435,2741.37%
Riverwater Partners LLC 15,553$1,393,2381.27%
KINGDON CAPITAL MANAGEMENT, L.L.C. 111,100$9,952,3381.15%
Lisanti Capital Growth, LLC 78,425$7,025,3121.11%
Aristotle Capital Boston, LLC 311,666$27,919,0540.90%
ROYCE & ASSOCIATES LP 947,550$84,881,5290.86%
CHASE INVESTMENT COUNSEL CORP 18,770$1,6810.84%
Virtus Investment Advisers, Inc. 13,662$1,223,8420.83%
View complete list of HAEMONETICS CORP shareholders